The dopamine D 2 receptors exist in two states: a high-affinity state (D 2 high ) that is linked to second messenger systems, is responsible for functional effects, and exhibits high affinity for agonists; and a low-affinity state that is functionally inert and exhibits lower affinity for agonists. The dopamine D 3 receptors have high-affinity for agonist (eg dopamine) and the existence of the two affinity states is controversial. Although preclinical studies in animal models of psychosis have shown a selective increase of D 2 high as the common pathway to psychosis, the D 3 has been suggested to be involved in the pathophysiology of psychosis. We report the first study of the D 2 high and D 3 in schizophrenia using the novel PET radiotracer, [
INTRODUCTION
It is well established that the dopamine D 2/3 receptors are the target of most antipsychotic drugs, though it remains unclear whether the D 2/3 receptors are involved in the pathophysiology of psychosis. An important recent development has been the evidence from preclinical models indicating that the 'high-affinity state' of the dopamine D 2 receptors (D 2 high ) is elevated in psychosis (Seeman et al, 2005b) . The dopamine D 2 and D 3 receptors are members of the G-protein-coupled receptors (GPCR) family. The D 2 receptor exists in two inter-convertible states: a G-proteincoupled state which has a high affinity for agonist binding and is responsible for the functional effects of dopamine; and a G-protein-uncoupled state which is a functionally inert state with a low-affinity for dopamine. On the other hand, the existence of the G-protein-coupled and uncoupled states of the D 3 receptors is controversial (Freedman et al, 1994; Seeman et al, 2005a; Sokoloff et al, 1992) , due to the inability of the G-protein analogs (eg guanilylimidodiphosphate, GppNHp) to shift it from the high-to the lowaffinity state (Vanhauwe et al, 2000) . Nevertheless, the D 3 receptor has at least 20-fold higher affinity than D 2 for dopamine (Freedman et al, 1994; Seeman et al, 2005a; Sokoloff et al, 1992) .
Data from over a dozen preclinical animal models of psychosis (eg amphetamine sensitization, phencyclidine sensitization, ethanol withdrawal, hippocampal lesion) (Seeman et al, 2005b) suggests that there is a selective elevation of high-affinity states in psychosis. Though, the method of distinguishing high-from low-affinity states in vitro involves the addition of high concentrations of Gprotein analogs, a method that is not feasible in humans. Molecular imaging techniques such as positron emission tomography (PET) allow for the in vivo study of brain receptors; but, until recently, the available radioligands for D 2 D 3 receptors allowing for a prominent signal from the striatum, globus pallidus (GP), substantia nigra (SN), and anterior thalamus (Freedman et al, 1994; Graff-Guerrero et al, 2008; Narendran et al, 2006; Seeman et al, 1993; Willeit et al, 2006) . It shows at least three critical differences compared to antagonist radiotracers. First, unlike antagonist radiotracers which do not distinguish between the lowand high-affinity states, [ 11 C]-( + )-PHNO is assumed to bind preferentially to the high-affinity states of the receptors Seeman et al, 2007) .
Second, ( + )-PHNO has a higher in vitro and in vivo affinity for D 3 than for D 2 receptors. In vitro, Freedman et al (1994) and Parker et al (2006) reported that ( + )-PHNO has more than 10-fold higher affinity for D 3 than for D 2 using conventional in vitro techniques, though Seeman et al (2005a) reported that ( + )-PHNO has a higher affinity for the D 2 high than D 3 high ) using in vitro analysis in the presence of GppNHp. In vivo, Narendran et al (2006) (Narendran et al, 2006; Rabiner et al, 2007b Rabiner et al, , 2008 . However, this higher sensitivity was not found in an ex vivo dissection study in awake rodents (McCormick et al, 2008) , though it is suggested by the study in awake and healthy humans . The cause of this discrepancy between studies is still elusive, though the cat and human studies suggest that [ (GP and SN) , for the first time it has provided an opportunity to explore directly the suggested involvement of the dopamine D 3 receptors in schizophrenia (Griffon et al, 1995; Gurevich et al, 1997; Joyce and Gurevich, 1999) .
The current study was aimed to compare the [ 
MATERIALS AND METHODS

Clinical Sample
This study has been approved by the local Research Ethics Board and by Health Canada. Twenty-six subjects were included: 13 drug-free patients and 13 healthy controls. The participants provided written informed consents after the study procedures and risks were explained. They were excluded if they had a current diagnosis of substance abuse or dependence at screening, positive result in urine drug screen at enrollment or before any of the PET scans, history of clinically significant physical illness, pregnant or lactating women at screening or positive urine pregnancy test before PET scans, or metal implants that would preclude the MRI scan.
The patients were evaluated before PET scan with the clinical global impression (CGI) and positive and negative syndrome scale (PANSS).
The patients had the diagnosis of schizophrenia or schizophreniform disorder corroborated with the MINIPlus structured interview (Sheehan et al, 1998) . The age range for inclusion was from 18 to 50 years old. The patients were drug free for at least 2 weeks and were excluded if they had been exposed to depot antipsychotic in the past 2 years; had a minimum PANSS total score of 55, score of 43 on at least two PANSS psychosis items (P1, P2, P3, P5, or P6) or 44 on one psychosis item; and CGI severity score X4 (moderately ill).
The healthy controls were recruited through local advertisement. Psychiatric disorders were excluded using the MINI-Plus structured interview (Sheehan et al, 1998) . The age range for inclusion was from 18 to 50 years old. Subjects with any medical or neurological conditions or with axis I psychiatric diagnoses were excluded from the study. Similarly, subjects with substance abuse (other than smoking) within 6 months before their baseline visit were not included. Participants were asked to consume no more than their usual amount of coffee (and if smokers, cigarettes) on the day of PET examination, and to abstain from alcohol intake 24 h before PET scans. Standard urine tests for psychotropic substances were performed at inclusion and immediately before PET scan. Pregnancy was excluded using serum analysis at inclusion and urine pregnancy tests before each scan.
[
C]-( + )-PHNO Synthesis
The radiosynthesis of [
11 C]-( + )-PHNO has been described in detail elsewhere (Wilson et al, 2005) . Briefly, [ 
Positron Emission Tomography Imaging
Studies were performed using a high-resolution brain PET camera system, HRRT (Siemens Molecular Imaging, Knoxville, TN), which measures radioactivity in 207 brain slices with an interslice distance of 1.2 mm. The in-plane resolution of the scanner is approximately 2.8 mm fullwidth-at-half-maximum. Transmission scans were acquired using a 137 Cesium single photon point source to provide attenuation correction. The emission data were acquired with a head fixation system during PET scans to avoid movement during the acquisition. After being placed on the scanning table, a total of 329±59 MBq (8.9±1.6 mCi) with a specific activity of 955.9 ± 295 mCi/mmol (range: 407-1790 mCi/mmol) and a mass of 2.33 ± 0.39 mg (range: 1.2-3.3 mg) of [
11 C]-( + )-PHNO was injected as a bolus followed by a flush with 2 ml saline into an intravenous line placed in an antecubital vein. Scanning data were acquired for 90 min after the injection. Once scanning was completed, the data were reframed into 30 frames (1-15 of 1 min duration and 16-30 of 5 min duration). From the 26 participants in this study, one healthy control experienced transient mild nausea. This was presented few minutes (B10 min) after [ 
MRI Imaging
Subjects undertook a proton density image (TE ¼ 17, TR ¼ 6000, FOV ¼ 22 cm 2D, 256 Â 256, slice thickness of 2 mm, NEX ¼ 2) acquired on a 1.5T Signa scanner (General Electric Medical Systems, Milwaukee, WI). These images were used for the analysis of the PET scans.
Image Analysis
The time activity curves (TACs) from the regions of interest (ROIs) caudate, putamen, ventral striatum (VS), GP, SN, and cerebellar cortex were obtained from the dynamic [ 11 C]-( + )-PHNO PET images in native space with reference to co-registered MRI image as previously described (GraffGuerrero et al, 2008; Rusjan et al, 2006; Willeit et al, 2008) . The ROI in the anterior thalamus was drawn manually using the Analyze Software Version 6.0 (AnalyzeDirect, Lenexa, Kansas) in the anterior part of the thalamus as observed in the first axial projection where putamen and thalamus can be shown. The co-registration of the MRI to the PET space image was carried out using the normalized mutual information algorithm as implemented in SPM2 (SPM2, Welcome Department of Cognitive Neurology, London; http://www.fil.ion.ucl.ac.uk/spm).
The TACs were obtained using a in-house software for semi-automated generation of ROIs (Rusjan et al, 2006) . The quantitative estimate of binding was estimated using the simplified reference tissue method (Lammertsma and Hume, 1996) with the cerebellar cortex as reference region. This method has been validated to reliable estimate the binding potential no-displaceable (BP ND ), which compares the concentration of radioligand in the receptor-rich region to the receptor-free region (Innis et al, 2007) , and has been validated for use with [
11 C]-( + )-PHNO . The BP ND s were estimated using the PMOD v2.7 software (PMOD Technologies Ltd, Zurich, Switzerland). Parametric voxel-wise BP ND maps from the dynamic images in native space were generated according to the method of Gunn et al (1997) with the cerebellum as reference region and as implemented in PMOD v2.7 software (PMOD Technologies Ltd). The BP ND map images were spatially normalized into the Montreal Neurological Institute brain space by nearest neighbor interpolation and with a voxel size fixed in 2 Â 2 Â 2 mm using the SPM2 software (Friston, 1995) . The normalized images were smoothed with a Gaussian filter in each coordinate direction with a kernel of 4 mm.
Statistical Analysis
The analysis was made using the Statistical Program for the Social Sciences (version 15.0; SPSS, Chicago, IL). Variables were presented as mean±standard deviation (SD). Demographic and clinical characteristics were compared between patients and controls by using Mann-Whitney U-test (gender) on categorical data and independent sample t-tests on continuous data (age). Analysis of variance with Bonferroni correction for multiple comparisons as a post hoc was performed to compare the BP ND s between drug-free patients and sex-and age-matched healthy controls per ROI (caudate, putamen, VS, GP, SN, and anterior thalamus). Pearson's product moment correlations between PANSS (total and subscales) and BP ND s were estimated. Repeated measures analysis of variance was performed to compare the standardized radioactivity in the cerebellum (within subjects factor) between drug-free patients and sex-and age-matched healthy controls (between subjects factor). The significance was always assumed at po0.05.
The voxel-wise comparison between BP ND maps, of drugfree patients and sex-and age-matched healthy controls, was performed with a two sample t-tests as implemented in SPM2. We reported areas only if they met the joint criteria of (a) p(uncorrected)o0.001; (b) an extent X10 voxels; and (c) in the caudate, putamen, GP, VS, midbrain, and anterior thalamus. Additionally, the statistically significant a priori regions would be corrected for multiple comparisons using the false discovery rate (FDR) approach.
RESULTS
The characteristics of the patients and controls are summarized in Table 1 . There were no differences between groups in age (drug-free patients mean ¼ 25.8 ± SD ¼ 5.9 years; healthy controls ¼ 26.8 ± 6.4 years, t ¼ À0.40, p ¼ 0.69) and in gender (drug-free patients ¼ 9 men; healthy controls ¼ 9 men; Mann-Whitney U-test ¼ 84.5, p ¼ 1.0). No differences emerged between drug-free patients and ageand sex-matched healthy controls in the BP ND in any of the ROI (F(6,19) ¼ 0.671, p ¼ 0.674). The BP ND (mean±SD) in the caudate for controls was 2.1 ± 0.2 and for patients was 2.2 ± 0.4 (p ¼ 0.52, pair-wise Bonferroni corrected); putamen: controls ¼ 2.6±0.3 and patients ¼ 2.6±0.2 (p ¼ 0.50); VS: controls ¼ 3.1 ± 0.4 and patients ¼ 3.2 ± 0.7 (p ¼ 0.63); GP: controls ¼ 2.9 ± 0.6 and patients ¼ 2.7 ± 0.5 (p ¼ 0.51); SN: controls ¼ 1.5±0.6 and patients ¼ 1.3±0.4 (p ¼ 0.33); thalamus: controls ¼ 1.2 ± 0.2 and patients ¼ 1.1 ± 0.3 (p ¼ 0.43) (Figure 1 ). This result was corroborated by the voxel-wise comparison of the BP ND maps between drug-free patients and controls which did not show any differences (Figure 2) . Moreover, the BP ND did not correlate with the severity of the illness as measured by the PANSS even before correction for multiple comparisons (Table 2) .
DISCUSSION
This study represents the first comprehensive investigation of the dopamine D 2 receptors in the high-affinity state (D 2 high ) and the D 3 receptors in patients. Contrary to our expectation based on preclinical data, we did not find evidence for elevated D 2 high in untreated patients with schizophrenia or schizophreniform disorder during acute psychosis.
The high-affinity state hypothesis has been sustained in many preclinical models of psychosis (Seeman et al, 2005b) and has been indirectly suggested by dopamine depletion studies in patients (Abi-Dargham et al, 2000) . Our results in drug-free patients failed to support this hypothesis. Although the reason for this discrepancy between predictions from in vitro data and findings in patients is not clear, several issues need to be considered.
First, the methods of measuring the high-affinity state in vitro and in patients are very different. The in vitro studies include competition assays between antagonist radiotracers and agonist ligands in the presence of non-hydrolysable GTP analogs (GppNHp), the latter converting the receptor from its high-affinity state to its low-affinity state (De Lean et al, 1980; Seeman et al, 2002 Seeman et al, , 2005b . This differs from the approach in humans which involves a direct study of the high-affinity states with an agonist radioligand. Second, there is ongoing debate as to the measurability of high-affinity state in vivo: eg Sibley et al (1983) identified both high-and low-affinity binding sites in membrane cells, but only low-affinity sites on the same intact cells. However, Seeman (2008) . On the other hand, studies in anesthetized cats , anesthetized nonhuman primates (Narendran et al, 2004; Seneca et al, 2006) , and awake humans showed greater displacement with an agonist radiotracer ( 11 C]-raclopride (McCormick et al, 2008) . These studies suggest that although agonist radiotracers do show a distinct binding profile in vivo, the exact difference varies as a function of the ligand and the tissue/animal characteristics. Finally, it is theoretically possible that an increase in the D 2 high and/or D 3 is indeed present in acute psychotic state in schizophrenia, but this may be masked by the presence of abnormal high levels of dopamine in the synaptic cleft. The abnormal high levels of dopamine in psychosis has been indirectly shown after an amphetamine challenge (AbiDargham et al, 1998), but the dopamine striatal synthesis capacity has reliably been found higher than in controls (Dao-Castellana et al, 1997; Hietala et al, 1999; Huttunen et al, 2007; Reith et al, 1994) .
Moreover, if the density of receptors configured in the high-affinity state is extremely high as suggested in normal conditions (B80%) (Narendran et al, 2005) , the difference between patients and controls may be below the resolution of the PET technique. One approach to uncover the differences and to test this hypothesis would require depleting dopamine in patients before imaging studies (Abi-Dargham et al, 2000) . We did not deplete dopamine levels and thus cannot definitively rule out a change in D 2 high /D 3 receptors which may have been cancelled by the ambient increase in endogenous dopamine. This is not just a theoretical concern, because studies by Abi-Dargham et al (2000) have shown that patients not only have higher baseline occupancy of dopamine receptors by dopamine, but also that when they are depleted of dopamine, they reveal a higher number of absolute D 2 receptors (AbiDargham et al, 2000) . Thus, a study depleting dopamine would be very critical in definitively resolving this issue.
The ROI and voxel-wise analyses did not reveal any difference in the D 3 -rich areas (GP and SN) between patients and controls. These results disagree with a previous postmortem study (Gurevich et al, 1997) , including drugfree patients with schizophrenia, describing twofold increase in the total number of D 3 receptors. The reason of this discrepancy with our results is unclear. But, differences in the sample characteristics between postmortem studies and our data such as age (old vs young), length of illness (years vs months), and previous exposure to antipsychotic medications (Graff-Guerrero et al, 2007) may help to explain the discrepancy on the results.
The current study also provides the first insight to the status of the D 3 receptors in the schizophrenia, as the [ 11 C]-( + )-PHNO signal in the SN is predominantly related to D 3 (Graff Rabiner et al, 2007a, b) . The SN (midbrain) is important because it is the origin of the nigrostriatal dopaminergic system and the D 3 receptors in the SN are autoreceptors (Diaz et al, 2000) . Thus alterations in these receptors could contribute to the hyperactivity of this midbrain dopamine system which is believed to play an important role in the genesis of schizophrenic symptoms (Murray et al, 2008) . However, we do not find support for an alteration of the D 3 in the SN.
Another issue to consider is that the [ or D 3 is also secure because a change in either of these should have led to an increase in the overall BP ND and we do not observe that. There is of course the hypothetical possibility that a simultaneous increase in D 2 high coupled with a decrease in D 3 (or vice versa) could hide a true finding. But, there is no data in the literature that suggest such possibility.
We did not record the smoking status of the healthy controls. This limitation may be important in the light of the effect of cigarette consumption, craving and its mood or hedonic effect on the dopamine system (Barrett et al, 2004; Brody et al, 2008; Montgomery et al, 2007) , and the fact that patients with schizophrenia are more likely to be smokers than general population (de Leon and Diaz, 2005) . However, given that we found no effect of smoking within our patients with schizophrenia (three smokers vs 10 nonsmokers) (data not shown), we think that it is unlikely that smoking alone could have obscured differences between patients and controls.
The lack of a full kinetic analysis is another potential limitation. This approach would have allowed for the direct estimation of the BP in the ROIs, without the assumption of equivalent nonspecific and free fraction in the reference region. However, our data showed that the cerebellar uptake in the drug-free patients and sex-and age-matched healthy controls was not different (Figure 3 ; F(1,24) ¼ 0.34, p ¼ 0.56) and, therefore, it is unlikely that a true finding could have been obscured by differences in the reference region.
The current study represents the first effort to measure the D 2 high and D 3 receptors in drug-free patients with psychotic disorders (schizophrenia-spectrum disorders). Our results indicate that patients in an acute psychotic episode do not exhibit an increase of the D 2 high or D 3 receptors in comparison to sex-and age-matched healthy controls. We cannot rule out the possibility that any difference of the D 2 high or D 3 were occluded by endogenous dopamine. The next step to definitively rule out such a possibility would require studies using [ 
